<DOC>
	<DOCNO>NCT01098162</DOCNO>
	<brief_summary>The purpose study systematically prospectively collect data patient partial-onset seizure routine clinical practice set receive adjunctive Vimpat® . The observed population patient one baseline antiepileptic drug . Seizure control tolerability data evaluate .</brief_summary>
	<brief_title>Vimpat® Added Adjunctive Therapy One Baseline Antiepileptic Drug</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Epilepsies , Partial</mesh_term>
	<mesh_term>Lacosamide</mesh_term>
	<mesh_term>Anticonvulsants</mesh_term>
	<criteria>The patient 's treatment must accordance local marketing authorization ( MA ) Vimpat® The decision prescribe Vimpat® make physician independently his/her decision include patient study The Vimpat® treatment start longer 2 week study inclusion patient The patient must diagnosis Epilepsy PartialOnset Seizures Based physician 's clinical judgment , patient 's seizure activity control sufficiently current monotherapy patient 's best interest prescribe adjunctive Vimpat® In accordance Summary Product Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Lacosamide</keyword>
	<keyword>Vimpat®</keyword>
	<keyword>Epilepsy</keyword>
	<keyword>Partial-Onset Seizures</keyword>
	<keyword>Adjunctive therapy</keyword>
</DOC>